NDAORALSOLUTION
Approved
Jan 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRIMSOL is an oral solution formulation of trimethoprim hydrochloride, a dihydrofolate reductase inhibitor used to treat bacterial urinary tract infections. It is a small-molecule antibiotic that works by inhibiting bacterial DNA synthesis. The solution formulation enables flexible dosing for patients who may have difficulty swallowing tablets.
LOE Approaching
Product is in late-stage maturity with LOE approaching; teams should expect transition planning and potential downsizing.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PRIMSOL as a pharma professional typically means supporting a stable, mature brand with limited growth upside and increasing generic competition. Career development on this product is best suited for professionals building experience in lifecycle management, cost containment, and transition planning rather than launch or growth initiatives.
Brand ManagerField Sales Representative
Worked on PRIMSOL at TerSera Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.